Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FBRX
SellHot AirForte Biosciences, Inc. · Healthcare · United States · $1.6B · Avg Vol: $54M/d
COMPANY DESCRIPTION
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for autoimmune and inflammatory diseases. The company's primary asset is FB-102, a proprietary therapeutic candidate designed to address significant unmet medical needs in immunology. It operates as a high-risk, high-reward biotechnology developer, leveraging scientific expertise to advance its pipeline through early-to-mid-stage clinical trials.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.82 | -1.77 | -3.80 | -4.71 | — | -4.57 | -4.48 | -4.08 | — |
| Shares | 20.5M | 20.5M | 20.5M | 12.9M | -36.8% | — | — | — | — |
| Debt | — | — | — | — | — | — | — | — | — |
| Equity | 38.8M | 35.3M | 52.5M | 61.0M | 16.3% | — | — | — | — |
| Op CF | -8.2M | -28.7M | -30.7M | -50.9M | — | -72.0M | — | — | — |
| Inv CF | 0 | 47.0K | -36.0M | 36.2M | — | — | — | — | — |
| Fin CF | 7.2M | 24.7M | 51.9M | 69.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FBRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FBRX | Forte Biosciences, Inc.(you) | $1.6B | 28 | Sell |
| VIR | Vir Biotechnology, Inc. | $1.8B | 29 | Sell |
| BCAX | Bicara Therapeutics Inc. | $1.6B | 30 | Sell |
| ZYME | Zymeworks Inc. | $2.0B | 28 | Sell |
| LBRX | LB Pharmaceuticals Inc | $1.5B | 32 | Sell |
| ANAB | AnaptysBio, Inc. | $1.7B | 34 | Sell |
| CGEM | Cullinan Therapeutics, Inc. | $1.3B | 26 | Sell |
| XNCR | Xencor, Inc. | $1.9B | 25 | Sell |
| ANRO | Alto Neuroscience, Inc. | $1.4B | 32 | Sell |
| TRVI | Trevi Therapeutics, Inc. | $2.4B | 28 | Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%